1 – 13 of 13
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Fifth Åland Island conference on von Willebrand disease
(
- Contribution to journal › Article
- 2013
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article
- 2012
-
Mark
von Willebrand's disease: a report from a meeting in the Åland islands.
(
- Contribution to journal › Article
- 2011
-
Mark
Recommendations for assessment, monitoring and follow-up of patients with haemophilia.
2011) In Haemophilia(
- Contribution to journal › Article
-
Mark
The pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors
(
- Contribution to journal › Published meeting abstract
- 2010
-
Mark
A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.31-31(
- Contribution to journal › Published meeting abstract
-
Mark
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
(
- Contribution to journal › Article
- 2009
-
Mark
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
(
- Contribution to journal › Article
-
Mark
European curriculum for thrombosis and haemostasis.
(
- Contribution to journal › Article
- 2008
-
Mark
High purity, double virus-inactivated VWF/FVIII concentrate in long term prophylaxis of von Willebrand disease - experience from prospective clinical trials and German post-licensure surveillance
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.12-12(
- Contribution to journal › Published meeting abstract
-
Mark
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors
(
- Contribution to journal › Article
- 2007
-
Mark
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
- 2006
-
Mark
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article